Lu177‐PSMA therapy for men with advanced prostate cancer: 18 months survival analysis in a single Australian tertiary institution
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Medical Imaging and Radiation Oncology"
DOI: 10.1111/1754-9485.13182
Abstract: Radioligand therapies, or ‘theranostics’, have an emerging role in patients with metastatic castration‐resistant prostate cancer (mCRPC). Lutetium‐177 (Lu), targeting prostate‐specific membrane antigen (PSMA), has demonstrated promising outcomes including reduced disease progression and improved overall survival.… read more here.
Keywords: lu177 psma; prostate cancer; therapy men; psma therapy ... See more keywords